Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nifedipine ER and Omeprazole/Sodium Bicarbonate DDI Study
NCT03100838Phase 1Completed
- Sponsor
- Food and Drug Administration
- Start
- Mar 2017
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nifedipine GITS in hypertension (HTN) and angina pectoris (4 arms), sponsored by Food and Drug Administration. Primary endpoints: Maximum Plasma Concentration at 48 hours, Time at Maximum Plasma Concentration at 48 hours and 2 more. Started Mar 2017; status: completed.
02
Drugs
nifedipine GITS
03
Conditions
hypertension (HTN)angina pectoris
Beyond the preview
Go deeper on NCT03100838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03100838.